Lp(a)-Hyperlipoproteinämie - Prof. Dr. Florian Kronenberg (Innsbruck)

Prof. Dr. Florian Kronenberg erläutert die Bedeutung von Diagnostik und Therapie der Lp(a)-Hyperlipoproteinämie zur Prävention und Therapie kardiovaskulärer Erkrankungen.
Prof. Dr. Florian Kronenberg ist Direktor der Genetischen Epidemiologie am Department für Genetik der Medizinischen Universität Innsbruck, und Erstautor der Konsensusstatements "Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis" der European Atherosclerosis Society.

Impulsvortrag Prof. Kronenberg
02:20 Was ist Lp(a)?
12:30 Ist Lp(a) ein kausaler Risikofaktor?
29:25 Lp(a) zur Risikoabschätzung
31:57 Management des erhöhten Lp(a)
41:03 Fragen und Antworten


Das Gespräch wurde am 06.11.2023 geführt. Moderatoren: Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern), Dr. Insa Emrich (Homburg) und Prof. Dr. Gunnar Heine (Frankfurt am Main).

Weitere Informationen:

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL.
Eur Heart J 2022
doi: 10.1093/eurheartj/ehac361

Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL.
Atherosclerosis 2023
doi: 10.1016/j.atherosclerosis.2023.04.012

Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study.
Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J.
Circulation 1999
doi: 10.1161/01.cir.100.11.1154

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators.
N Engl J Med 2020
doi: 10.1056/NEJMoa1905239

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.
Gudbjartsson DF et al.
J Am Coll Cardiol 2019
doi: 10.1016/j.jacc.2019.10.019

Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.
Yeang C, Witztum JL, Tsimikas S.
J Lipid Res 2021
doi: 10.1016/j.jlr.2021.100053

Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study.
Strandkjær N et al.
J Clin Endocrinol Metab 2022
doi: 10.1210/clinem/dgab734.

Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic.
de Boer LM et al.
Atherosclerosis 2022
doi: 10.1016/j.atherosclerosis.2022.03.004

The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome.
Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H.
Kidney Int 2004
doi: 10.1111/j.1523-1755.2004.00418.x.

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
Madsen CM, ..., Nordestgaard BG. Arterioscler Thromb Vasc Biol 2020
doi: 10.1161/ATVBAHA.119.312951

Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures.
Miller WG et al.
Clin Chem 2010
doi: 10.1373/clinchem.2009.142810.

Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood.
Nowak-Göttl U et al.
Blood 1999
PMID: 10572079

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
Nordestgaard BG, Langsted A.
J Lipid Res 2016
doi: 10.1194/jlr.R071233

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis.
Lamina C, Kronenberg F; Lp(a)-GWAS-Consortium.
JAMA Cardiol 2019
doi: 10.1001/jamacardio.2019.1041

Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study.
Deshotels MR et al.
J Am Heart Assoc 2022
doi: 10.1161/JAHA.122.026762

Phase 3 Studien zur Lp(a) Senkung:

Lp(a)HORIZON (Pelacarsen)
https://classic.clinicaltrials.gov/ct...

OCEAN(a) Outcomes (Olpasiran)
https://classic.clinicaltrials.gov/ct...


Der Lp(a) risk calculator ist unter http://www.lpaclinicalguidance.com kostenfrei abrufbar.